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microRNAs is associated with lymph node
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Kelly A Avery-Kiejda1,2*, Stephen G Braye3, Andrea Mathe1,2, John F Forbes4,5 and Rodney J Scott1,2,3Abstract
Background: Breast cancer is the most common malignancy that develops in women, responsible for the highest
cancer-associated death rates. Triple negative breast cancers represent an important subtype that have an aggressive
clinical phenotype, are associated with a higher likelihood of metastasis and are not responsive to current targeted
therapies. miRNAs have emerged as an attractive candidate for molecular biomarkers and treatment targets in breast
cancer, but their role in the progression of triple negative breast cancer remains largely unexplored.
Methods: This study has investigated miRNA expression profiles in 31 primary triple negative breast cancer cases and
in 13 matched lymph node metastases compared with 23 matched normal breast tissues to determine miRNAs
associated with the initiation of this disease subtype and those associated with its metastasis.
Results: 71 miRNAs were differentially expressed in triple negative breast cancer, the majority of which have previously
been associated with breast cancer, including members of the miR-200 family and the miR-17-92 oncogenic cluster,
suggesting that the majority of miRNAs involved in the initiation of triple negative breast cancer are not subtype
specific. However, the repertoire of miRNAs expressed in lymph node negative and lymph node positive triple negative
breast cancers were largely distinct from one another. In particular, miRNA profiles associated with lymph node negative
disease tended to be up-regulated, while those associated with lymph node positive disease were down-regulated and
largely overlapped with the profiles of their matched lymph node metastases. From this, 27 miRNAs were identified that
are associated with metastatic capability in the triple negative breast cancer subtype.
Conclusions: These results provide novel insight into the repertoire of miRNAs that contribute to the initiation of and
progression to lymph node metastasis in triple negative breast cancer and have important implications for the
treatment of this breast cancer subtype.
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Breast cancer is the most common malignancy that de-
velops in women worldwide, its incidence continues to
rise and it is responsible for the highest cancer-associated
death rates [1]. It is an extremely heterogeneous disease,
made up of a number of different subtypes. Classification
of breast cancer into subtypes can be partly attributed to* Correspondence: Kelly.Kiejda@newcastle.edu.au
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distribution, and reproduction in any mediumthe presence or absence of receptors for the hormones es-
trogen (ER), progesterone (PR) and human epidermal
growth factor 2 (HER2). Triple negative breast cancer
(TNBC) represents a particularly important clinical sub-
type, characterised by an absence of ER, PR and HER2
and which therefore lacks common targets used for anti-
hormone therapies [2,3]. Although TNBCs comprise only
a small percentage of all breast cancers diagnosed (10-
24%), they have been recently the subject of intense inves-
tigation because of their aggressive clinical behaviour.
Patients who are diagnosed with TNBC are of younger
age, tend to develop tumours of larger size, and have an
increased likelihood of distant metastasis and death withinntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Avery-Kiejda et al. BMC Cancer 2014, 14:51 Page 2 of 14
http://www.biomedcentral.com/1471-2407/14/515 years of diagnosis [2,3]. Thus, TNBCs represent a major
clinical problem for which targeted therapies are currently
not available.
microRNAs (miRNAs) are a class of small (~22 nucle-
otides) non-coding RNAs that control gene expression
by targeting mRNAs and triggering either translational
repression or RNA degradation [4]. miRNAs have emerged
as an attractive candidate for molecular biomarkers and
novel therapeutic targets in cancer because of their stabil-
ity, ease of detection and their ability to act as endogenous
antisense regulators of entire gene sets that regulate can-
cer growth [5].
Several studies have identified critical roles for miRNAs
in breast cancer. Iorio and colleagues were the first to re-
port significant deregulation in miRNA expression profiles
in breast cancer when compared to normal breast tissue,
where they showed that the expression of several miRNAs
was associated with breast cancer subtypes and clinico-
pathological features including hormone receptor status,
clinical stage and proliferation index [6], suggesting that
miRNA expression in breast cancer may have diagnostic
and prognostic value. Since then, several miRNAs have
been identified that have prognostic significance, including
miR-210, miR-126, miR-21 and miR-205 [7-11]. However,
the clinical cohorts used to generate these miRNA profiles
have been highly heterogeneous, in regards to clinicopath-
ological variables (e.g. grade, tumour size, subtype). More-
over, because these studies have concentrated on using
miRNA profiles to better classify breast cancer subtypes,
there are few studies that have profiled all miRNAs within
a particular breast cancer subtype and even fewer that
have used matched normal tissue as controls in these ana-
lyses; and so it is plausible that miRNAs important in dis-
ease initiation and progression that are subtype specific
have been missed. TNBCs are distinct from ER-, PR- posi-
tive tumours at the molecular level and this classification
has clinical implications [12]. Therefore, the identification
of miRNAs that control TNBC initiation and progression
could identify individuals that have more aggressive dis-
ease and may also help to identify subgroups of patients
that are more responsive to particular treatments within
these subtypes.
The dissemination of primary cancer cells to the lym-
phatic system represents one of the first signs of meta-
static spread. In breast cancer, the number of positive
lymph nodes (LN) is known to have an inverse linear
correlation with prognosis and survival [13]. This is not
the case with TNBC, where it has been shown that any
LN involvement is associated with worse disease-free
and overall survival [14]. Therefore, identification of
miRNAs that are differentially expressed within LN me-
tastases in this highly aggressive breast cancer subtype
may serve as a better indicator of prognosis than miRNA
profiles derived from primary breast cancers.In this study, miRNA expression profiles of 31 primary
TNBCs were examined and compared to the profiles of
23 matched normal breast tissues to reveal miRNAs that
were differentially expressed in TNBC and that are po-
tentially associated with its initiation. In addition, by
comparing the miRNA expression profiles of lymph
node positive primary tumours and matched LN metas-
tases, we have identified a panel of miRNAs that are as-
sociated with metastatic capability in the TNBC subtype.
Methods
Study cohort and tissue sampling
Thirty-five formalin-fixed paraffin-embedded invasive
ductal carcinomas (IDCs) were obtained from the ar-
chives of the Hunter Area Pathology Service, John Hunter
Hospital, Newcastle, Australia. All patients were diag-
nosed with grade 3 IDC between the years of 2004–2009,
and were negative for ER, PR and HER2 as assessed
through routine diagnostic pathology (Additional file 1:
Supplementary Methods and Figure S1). Areas of tissue
representing histologically normal adjacent breast tissue
(NAT, where available), IDC and breast cancer metastases
(in LN) were identified and confirmed by a pathologist.
Micrometastases (<2 mm) were not used in the analysis.
None of the areas of selected NAT contained tumour tis-
sue and all were enriched for terminal duct lobular units
(>2 in biopsied area). Patient information is described in
Table 1. A 1.5 mm punch biopsy was used to punch tissue
cores from the paraffin blocks using haemotoxylin and
eosin stained sections of the same sample for guidance.
Tumour volume in the core biopsy was >70% of the total.
This study complies with the Helsinki Declaration with
ethical approval from the Hunter New England Human
Research Ethics Committee (Approval number: 09/05/20/
5.02). In accordance with the National Statement on Eth-
ical Conduct in Research Involving Humans, a waiver of
consent was granted for this study.
Extraction of RNA
Total RNA was extracted using the miRNeasy FFPE kit
(Qiagen, Doncaster, VIC, Australia). RNA was quantified
using the Quant-it RiboGreen RNA Assay kit (Invitro-
gen, Mulgrave, VIC, Australia) and purity assessed by
A260/A280 and A260/230 ratios (>1.8) using the Nanodrop.
The RNA integrity of selected samples was analysed
using the 2100 Bioanalyser and the RNA 6000 Nano kit
(Agilent Technologies, Mulgrave, VIC, Australia).
miRNA arrays
100 ng of total RNA was dephosphorylated and directly
labelled with Cy3 using the miRNA Complete Labelling
and Hyb Kit (Agilent Technologies). Labelled RNA was
hybridised to Human miRNA microarrays (Sanger Release
14.0) according to the manufacturers’ instructions (Agilent
Table 1 Demographic data of triple negative breast
cancer cases





Average (±SD) 58 ± 14 54 ± 14
Range 36–84 28–78
<50 4 (25%) 9 (47.3%)
50-69 8 (50%) 7 (36.8%)
>69 4 (25%) 3 (15.8%)
Tumour size (mm)
Average (±SD) 32 ± 12 32 ± 21
Range 12–60 12–100
<20 2 (12.5%) 4 (21%)
20-39 10 (62.5%) 12 (63.2%)
>39 4 (25%) 3 (15.8%)
No. of positive lymph
nodes




>3 0 6 (31.6%)
Normal adjacent tissue
Yes 9 (56.3%) 15 (78.9%)
No 7 (43.8%) 4 (21.1%)
Avery-Kiejda et al. BMC Cancer 2014, 14:51 Page 3 of 14
http://www.biomedcentral.com/1471-2407/14/51Technologies) and scanned on an Agilent High-resolution
C scanner.
miRNA array analysis
These miRNA array results have been deposited in Gene
Expression Omnibus (GEO) with Accession No. GSE38167.
Data from 15,000 probe features representing 904 unique
miRNAs was extracted using Agilent Feature Extraction
software (v10.7.3.1) and converted to background sub-
tracted signal intensities. The extracted data was imported
into Genespring GX (Agilent Technologies) where it was
log2 transformed and median normalised. Seven samples
did not meet quality control measurements recommended
by the manufacturer and were removed from the micro-
array analysis (1 IDC from a LN negative patient, 1 NAT
and 3 IDCs from LN positive patients; and 2 LN metasta-
ses). Of all the probes interrogated in this analysis, those
corresponding to 570 miRNA transcripts were present at
a signal intensity threshold above background in at least
one of the tissue samples. Unpaired t-tests were used to
identify miRNAs with significantly altered expression
(>2-fold, p < 0.05). To correct for false positive results, a
Benjamini and Hochberg False Discovery Rate (FDR) of
5.0% was used for multiple testing. Supervised hierarchical
cluster analysis was performed on miRNAs that werefound to be significantly different (>2 fold, p < 0.05, FDR <
0.05). Similarity in the expression patterns between
miRNAs was measured by Pearson’s correlation coefficient.
Biological targets of differentially expressed miRNAs
were identified by searching for the presence of con-
served 8mer and 7mer sites within genes that match the
seed region of each miRNA. Non-conserved sites were
also included in this analysis. This analysis was performed
using sRNA Target Base (starBase, http://starbase.sysu.
edu.cn/index.php) [15] which integrates data from 21 Ago
or TNRC6 CLIP-Seq sequence data sets with the target
prediction programs Target Scan, Pictar and miRanda.
The number of genes identified by each of these programs
and those in common between each of the programs is
shown in Additional file 1: Figure S2. Only those target
genes that were predicted by all three target prediction
programs (560 genes) were used for further pathway ana-
lysis. PANTHER [16] was used to annotate the biological
pathways that predicted miRNA target genes were in-
volved in as previously described [17]. Pathways with a p-
value <0.05 were considered to be significantly regulated
by the miRNAs.
To determine the significance of differentially expressed
miRNA families and clustered miRNAs; or to annotate
the function of differentially expressed miRNAs, a freely
available web-based resource, TAM (tool for annotations
of miRNAs), was used [18].
Semi-quantitative real-time PCR
Total RNA (5 ng) was reverse transcribed to generate
cDNA using the Taqman MicroRNA Reverse Transcrip-
tion Kit and Megaplex RT Human Primer Pools Set v3.0
(Applied Biosystems, Mulgrave, VIC, Australia) according
to the manufacturers’ instructions. cDNA was amplified
using the TaqMan PreAmp Master Mix with Megaplex
Human PreAmp Primer Pools Set v3.0 (Applied Biosys-
tems) according to the manufacturers’ instructions. Real-
time PCR analysis was performed in triplicate on all
samples (Table 1) using TaqMan Universal PCR mix No
AmpErase UNG and TaqMan MicroRNA Assays (Applied
Biosystems) according to the manufacturers’ instructions,
with results quantified on a 7500 real-time PCR system
(Applied Biosystems). The expression of the following
miRNAs was analysed for array validation: hsa-let-7a
(Assay ID: 377), hsa-let-7b (Assay ID: 2619), hsa-let-7c
(Assay ID: 379), hsa-miR-100 (Assay ID: 437), hsa-miR-
101 (Assay ID: 2253), hsa-miR-126* (Assay ID:451), hsa-
miR-26a (Assay ID: 405), hsa-miR-26b (Assay ID: 407),
hsa-miR-130a (Assay ID: 454), hsa-miR-29c (Assay ID:
587), hsa-miR-205 (Assay ID: 509), miR-210 (Assay ID:
512), RNU44 (Assay ID: 1094) and RNU49 (Assay ID: 1005).
The relative miRNA expression was calculated by normal-
ising the miRNA of interest to RNU44 (2-ΔCt). Relative ex-
pression of miRNAs was also calculated using a second
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expression patterns for the miRs analysed was observed
when normalised with RNU49 (examples shown in
Additional file 1: Figure S3). The relative expression of
RNU44 and RNU49 was not significantly different be-
tween the subgroups analysed and therefore served as an
appropriate normaliser for this analysis (Additional file 1:
Figure S3). All pre-amplified multiplex miRNA assays
were validated against uniplex miRNA assays to verify that
the multiplex reaction did not affect miRNA quantitation
(Additional file 1: Supplementary Methods, Table S1 and
Figure S4). hsa-miR-126* and hsa-miR-205 were outside
our range of acceptable PCR efficiencies and were not
used for further validations.Statistical analysis
The normality of the data distribution was tested using a
D’Agostino and Pearson Omnibus test. The values were
found not to have been sampled from a Gaussian distri-
bution and thus, non-parametric statistical tests were
used to compare the real-time PCR data. A two-tailed
Mann–Whitney U test was used to determine if there
was a statistically significant difference in the expression
of miRNAs between any two subgroups. The Kruskal-
Wallis rank test followed by a Dunn’s Multiple Correction
test was used to determine the statistical significance of
miRNA expression between multiple (>2) subgroups.
Analysis of the correlation between miRNA expression
and clinical parameters was performed using Spearman’s
correlation test. All analysis was performed using Graph-
Pad Prism (version 5.04) software (GraphPad software
Inc., La Jolla, CA, USA).Results
miRNAs differentially expressed in TNBC
To identify miRNAs associated with TNBC, expression
profiles were analysed in 35 grade 3 invasive ductal car-
cinomas (IDCs) compared to 24 matched normal adja-
cent tissue (NAT) specimens (Table 1). Seven samples
did not meet quality control measurements recom-
mended by the manufacturer and were removed from
the microarray analysis (refer to Methods). Seventy-one
of the miRNA transcripts were identified as being differ-
entially expressed between IDC and NAT (Figure 1A).
Supervised hierarchical clustering of these miRNAs
clearly separated NAT from IDC, suggesting that the ex-
pression of these miRNAs can discriminate these two
groups (Figure 1A). Five of the differentially expressed
miRNAs (miR-210, miR-100, miR-130a, let-7b, let-7c)
were verified by real-time PCR and were shown to be
significantly different in expression between IDC and
NAT in all cases (Figure 1B). In addition, the fold
change in expression (IDC versus NAT) of the fivemiRNAs was highly concordant (R2 = 0.9543) between
microarray and real-time PCR analysis, further confirm-
ing the validity of this approach (Figure 1C).
Of the 71 significantly altered miRNA transcripts, 39
showed increased expression and 32 showed decreased
expression in IDC when compared to NAT (Additional
file 1: Table S2). miRNAs are known to be located in
genomic clusters [19]. Several of the miRNAs that were
identified as being differentially expressed are clustered
within the same genomic region, and four of these gen-
omic clusters were significantly over-represented (p <
0.05): the miR-17-92 cluster (miR-17, miR-18a, miR19a,
miR-19b, miR-20a), the miR-106b cluster (miR-25, miR-
93, miR-106b), the miR-200a cluster (miR-200a, miR-
200b, miR-429) and the miR-106a cluster (miR-18b,
miR-19b, miR-20b, miR-363) (Additional file 1: Table S3).
miRNAs are commonly grouped in families based on the
similarity in their seed sequence. Three miRNA families
were significantly (p < 0.05) over-represented: the miR-17
family (miR-17, miR-18a, miR-18b, miR-20a, miR-20b,
miR-93, miR-106b), the miR-200 family (miR-200a, miR-
200b, miR-200c, miR-141, miR-429) and the miR-130
family (miR-130a, miR-130b, miR-301a) (Additional file 1:
Table S3). The majority of the differentially expressed
miRNAs have previously been implicated in breast cancer
including miR-200a, miR-200b, miR-200c, miR-21, miR-
210, miR-205 and miR-10b [7,8,10,11,20,21]; and their
regulation was concordant with previous studies. This
suggests that the majority of the miRNAs identified in this
study are relevant to the initiation of all breast cancers. In
addition, we identified 5 miRNAs: miR-130a, miR-1280,
miR-590-5p, miR-1308, miR-17*, which to the best of our
knowledge, have not previously been implicated in breast
cancer (Table 2). Of note, miR-130a has been shown to be
associated with chemotherapy response in ovarian cancer
and lung cancer cell lines, while miR-1280 has recently
been demonstrated to inhibit invasion and metastasis by
targeting ROCK1 when over-expressed in bladder cancer
[22-24]. miR-590-5p has been reported to enhance (via
the tumour suppressor PBRM1) or inhibit (via S100A10)
cell growth and invasion depending on the cellular con-
text, however, the function of miR-1308 and miR-17* has
not been extensively studied [25,26].
miRNAs differentially expressed in LN negative IDCs
compared to LN positive IDCs
To determine miRNAs that were differentially expressed
in patients with LN metastases, the primary breast can-
cers from 15 LN negative patients and 16 LN positive
patients were compared. In this analysis, there were no
miRNAs that were found to be significantly different.
Additionally, the comparison of NAT from node nega-
tive and node positive women yielded no significant dif-
ferences in miRNA profiles.
Table 2 Unique miRNAs identified as being differentially
expressed in triple negative breast cancer






Fold change in expression of 5 miRNAs found to be significantly different in
extracts from 31 TNBCs compared to extracts from 23 matched normal
adjacent tissue specimens (>2-fold difference, p < 0.05 and a false discovery
rate (FDR) = 5.0%).
Figure 1 miRNAs significantly different in triple negative breast cancer. A) Supervised hierarchical cluster analysis was performed on 71
miRNAs significantly altered between tumour (n = 31, red branches, top) and normal adjacent tissue samples (n = 23, blue branches, top).
Similarity in the expression patterns between miRNAs (branches shown on the left-hand panel) and between samples (branches shown on the
top panel) was measured using Pearsons correlation. Distances between clustered branches represent the average distances between miRNAs
and samples in the cluster. The height of each branch represents the degree of similarity within the cluster. miRNAs are coloured according to
their expression level, where up-regulated expression is represented by red, down-regulated expression is represented by blue, and equal expression is
represented by yellow. B) Relative quantification of miR-210, miR-100, miR-130a, let-7b and let-7c by real-time RT-PCR in normal (n = 24) and tumour
samples (n = 35). Results are shown as a scatter plot of the relative normalised expression (target/RNU44) of the target miRNA (2-ΔCt). Values represent
the median ± interquartile range. *p < 0.0001, **p = 0.0004. C) Correlation between real-time PCR and miRNA array results. Relative quantification of fold
change (IDC v NAT) in miR-210, miR-100, miR-130a, let-7b and let-7c between normal and tumour samples by real-time RT-PCR (2-ΔΔCt, y-axis) or
miRNA array (x-axis).
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In contrast to the report of Cascione et al. we undertook
an additional investigation examining the relationship
between lymph node positivity and miRNA expression
[27]. We determined the miRNA profiles of LN positive
and LN negative IDCs compared to their matched NAT.
From these analyses, 37 miRNAs were found to be al-
tered in LN negative patients, while 46 miRNAs were
found to be significantly different in LN positive patients
(Figure 2, Additional file 1: Tables S4 and S5). Super-
vised hierarchical clustering of these miRNAs completely
separated NAT from IDC into two distinct groups in LN
negative patients (Figure 2A) and was able to distinguish
Figure 2 miRNAs significantly different in triple negative breast
cancer with lymph node metastases. Supervised hierarchical
cluster analysis was performed on miRNAs significantly altered
between tumour (red branches, top) and normal adjacent tissue
samples (blue branches, top) in A) lymph node negative and
B) lymph node positive patients. Similarity in the expression patterns
between miRNAs (branches shown on the left-hand panel) and
between samples (branches shown on the top panel) was measured
using Pearsons correlation. Distances between clustered branches
represent the average distances between miRNAs and samples in
the cluster. The height of each branch represents the degree of
similarity within the cluster. miRNAs are coloured according to their
expression level, where up-regulated expression is represented by
red, down-regulated expression is represented by blue, and equal
expression is represented by yellow. C) Venn diagram representing
the overlap between miRNAs regulated in lymph node negative
patients (37 miRNAs, left-hand circle), lymph node positive patients
(46 miRNAs, right-hand circle) and in the lymph node metastases of
lymph node positive patients (63 miRNAs, bottom circle). D) Histogram
depicting the fold regulation of the 27 miRNAs (highlighted in red in
C) in tumour compared to NAT in lymph node negative tumours
(white), lymph node positive tumours (black) and lymph node metastases
(grey). Two-fold regulation is depicted by the red line.
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classified) from matched NAT (Figure 2B). Only 10 of
the miRNAs that were identified as being differentially
expressed in IDC versus NAT overlapped in LN negative
and LN positive patients and the direction of their regu-
lation (up, down) when compared to matched NAT, was
concordant (Figure 2C, Additional file 1: Tables S4 and
S5, miRNAs in bold). These included up-regulation of
miR-21 and down-regulation of miR-10b; which have
well known roles in breast cancer (Figure 2C; Additional
file 1: Tables S4 and S5). Interestingly, the majority of
miRNAs identified as being differentially expressed in
LN negative patients were up-regulated (34/37 miRNAs),
while the majority of differentially expressed miRNAs
were down-regulated (35/46 miRNAs) in LN positive pa-
tients (Figure 2, Additional file 1: Tables S4 and S5).
These results suggest that the repertoire of miRNAs
whose expression is altered in the primary breast
tumour when compared to the normal breast tissue is
distinct in LN positive and negative patients.
Of note, the five unique miRNAs that were differen-
tially regulated when all tumours were compared to all
normal tissues (Table 2), were not commonly regulated
when lymph node positive and negative cases were com-
pared separately to matched normal tissue. Instead, the
miRs that were positively regulated (miR-17*- 3.03, miR-
590-5p- 2.15, miR-1280- 2.10) when all tumours were
analysed became more highly up-regulated (miR-17*-
4.66, miR-590-5p- 3.13, miR-1280- 2.40) in the compari-
son of lymph node negative tumours versus matched
normal tissue, but were not regulated in lymph node posi-
tive tumours. In contrast, while miR-130a was down-
Avery-Kiejda et al. BMC Cancer 2014, 14:51 Page 7 of 14
http://www.biomedcentral.com/1471-2407/14/51regulated in the comparison of all tumour tissues (−2.21),
it became more strongly down-regulated in lymph node
positive tumours (−3.32) when they were compared to
matched normal tissues, and was not regulated in lymph
node negative cases. This supports our data, that there are
intrinsic differences between lymph node positive and
negative TNBCs: miRs are mainly down-regulated in pa-
tients with lymph node metastases, and up-regulated in
patients who do not have lymph node metastases and sug-
gests that it is these patients (i.e. lymph node positive or
negative tumours) that are driving the differential regula-
tion (negative and positive respectively) when all patients
are combined.
To determine miRNAs that were altered in LN metasta-
ses, the miRNA profile of LN metastases were compared
to those of NAT (9 matched and 5 unmatched) from LN
positive patients. From this analysis, 63 miRNAs were
found to be differentially expressed (Additional file 1:
Table S6). The majority of these miRNAs (58/63 miRNAs)
were down-regulated and largely overlapped with the pro-
file of their primary tumour (IDC, LN+; 32/63 miRNAs,
Figure 2C). Many of the miRNAs overlap with those iden-
tified by Cascione et al., with 33% (21/63) of the differen-
tially expressed miRNAs identified by our study also
showing differential regulation in normal versus LN me-
tastases comparisons in their study of TNBC [27]. No
miRNAs were differentially expressed when LN positive
primary IDCs and LN metastases were compared. This
suggests that the profile of miRNAs differentially ex-
pressed in primary breast cancers are maintained in LN
metastases from these tumours. This is also concordant
with the results of Cascione et al. who found very few dif-
ferentially expressed miRNAs in this comparison [27]. In
contrast, only five of the 63 miRNAs that were differen-
tially expressed in LN metastases were also differentially
expressed in LN negative primary IDC’s (Figure 2C) when
compared to NAT, suggesting that their miRNA profiles
are largely distinct.
We reasoned that miRNAs that are differentially
expressed in LN metastases and in the primary IDC of
patients with LN metastases, that are not differentially
expressed in patients who did not have LN metastases,
may represent some of the earliest changes associated
with metastatic progression. The overlap of the miRNA
profiles is shown in Figure 2C, where 27 miRNAs were
shown to meet these criteria. These concordantly regu-
lated miRNAs include three members of the let-7 family
(let-7a, -7b, -7c), two members of the miR-26 family
(miR-26a, -26b) and three members of the miR-199 fam-
ily (miR-199a-3p, -199a-5p, -199b-5p), suggesting that
these miRNAs regulate similar target genes (Table 3).
Furthermore, the list also contains miRNAs located
within the same genomic cluster as one another, the
let7a cluster (let-7a-3, -7b; and let-7a2, miR-100), themiR-195 cluster (miR-195, miR-497) and the miR-199a
cluster (miR-199a, miR-214), suggesting they are co-
ordinately regulated. With the exception of miR-210 and
miR-135b, all miRNAs were significantly down regulated
in the primary IDC and LN metastases when compared
to matched NAT, but were not significantly different in
primary IDCs from LN negative patients (Figure 2D and
Table 3). These results were verified by real-time PCR
for nine of the miRNAs (Figure 3), where the statistical
significance in the difference in expression of these miR-
NAs was largely confirmed, with the exception of miR-
101 and miR-29c, where the difference in expression of
these miRNAs between normal and tumour samples in
LN positive patients did not reach statistical significance.
Biological functions and pathways regulated by the
27 miRNAs associated with LN metastasis
To annotate the function of the 27 miRNAs, we per-
formed TAM analysis [18]. Through this analysis, the
majority of miRNAs were found to function as tumour
suppressor miRs (13/27 miRNAs) or were involved in
human embryonic stem cell regulation (11/27 miRNAs)
and these functions were significantly over-represented.
A number of miRNAs in this list are also known to
have functions in cell death and/or the cell cycle and
these functions were also significantly over-represented
(Additional file 1: Table S7).
We next used starBase and PANTHER to predict the
genes and signalling pathways regulated by these miR-
NAs. Ten pathways were predicted to be significantly
regulated by these miRNAs and many of these have
already been reported to be dysregulated in TNBCs in-
cluding the p53, EGFR1, Wnt and the TGFβ signalling
pathways (Table 4).
Correlation between miRNA expression and clinical
parameters
To determine if the expression of miRNAs verified in this
study by real-time PCR were independently related to age
at diagnosis, tumour size or the percentage of positive
LNs, we tested their association using Spearman’s Rank
correlation (Table 5). None of the miRNAs tested were in-
dependently associated with age at diagnosis or tumour
size. However, the expression of miR-101 was negatively
correlated with the percentage of LNs positive while the
negative correlation of let-7b and miR-29c with the per-
centage of LNs positive approached significance (Table 5).
Discussion
This study has investigated miRNA profiles in TNBC
cases to determine miRNAs whose expression is associ-
ated with the initiation of this breast cancer subtype and
those associated with its metastasis to the LN. We have
Table 3 miRNAs differentially expressed in triple negative breast cancer patients with lymph node metastases
Lymph node positive cases Lymph node negative cases
IDC v NAT LN met v NAT IDC v NAT
Systematic name Fold change p-value Fold change p-value Fold change p-value
hsa-let-7a −2.36 0.00419 −3.33 0.00042 1.05 ns
hsa-let-7b −2.99 0.00011 −4.67 0.00007 −1.30 ns
hsa-let-7c −3.84 0.00006 −6.34 0.00001 −1.72 ns
hsa-miR-100 −4.37 0.00176 −4.57 0.00331 −1.84 ns
hsa-miR-101 −2.61 0.01750 −3.30 0.02278 1.22 ns
hsa-miR-10a −2.37 0.02228 −4.64 0.00496 −1.78 ns
hsa-miR-125b −5.18 0.00010 −8.41 0.00001 −2.69 ns
hsa-miR-126 −2.72 0.00451 −3.76 0.00451 −1.50 ns
hsa-miR-126* −2.31 0.04409 −2.63 0.02725 −1.56 ns
hsa-miR-130a −3.32 0.01446 −6.61 0.00430 −1.32 ns
hsa-miR-135b 14.14 0.00012 6.92 0.02725 14.87 ns
hsa-miR-136 −6.18 0.00011 −9.58 0.00223 −3.42 ns
hsa-miR-143 −2.99 0.01750 −3.04 0.03718 −2.02 ns
hsa-miR-195 −5.70 0.00006 −10.02 0.00029 −2.50 ns
hsa-miR-1977_v14.0 −2.28 0.00377 −2.91 0.00069 −1.49 ns
hsa-miR-199a-3p −2.50 0.01750 −4.84 0.00451 −1.55 ns
hsa-miR-199a-5p −2.46 0.04409 −4.64 0.00869 −1.66 ns
hsa-miR-199b-5p −5.66 0.00011 −9.29 0.00021 −3.40 ns
hsa-miR-205 −4.65 0.02890 −5.18 0.01648 −1.82 ns
hsa-miR-210 4.56 0.00862 2.98 0.02389 4.01 ns
hsa-miR-214 −2.64 0.01360 −3.64 0.02023 −2.28 ns
hsa-miR-26a −2.67 0.01428 −3.84 0.00247 −1.00 ns
hsa-miR-26b −2.43 0.01681 −3.01 0.01308 −1.01 ns
hsa-miR-29c −2.33 0.04343 −2.69 0.03676 −1.12 ns
hsa-miR-320c −2.15 0.02461 −2.65 0.02023 −1.02 ns
hsa-miR-34a −2.12 0.02087 −3.59 0.00825 −1.11 ns
hsa-miR-497 −5.11 0.00006 −7.91 0.00029 −2.06 ns
Fold change in expression of 27 miRNAs found to be significantly different in extracts from 16 TNBC cases (lymph node positive) and their corresponding lymph
node metastases (13 cases) when compared to their matched normal adjacent tissue specimens (14 cases) (>2-fold difference, p < 0.05 and a false discovery rate
(FDR) = 5.0%). Expression of these miRNAs in lymph node negative cases (IDC n = 15, NAT n = 9) is shown for comparison. ns = not significant.
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http://www.biomedcentral.com/1471-2407/14/51identified a panel of 27 miRNAs that are associated with
breast cancer progression in TNBC.
miRNAs differentially expressed in TNBC
By comparing the miRNA profiles of primary breast tu-
mours to matched normal adjacent breast tissue, 71
miRNAs were identified as being differentially expressed.
The majority of the miRNAs identified in this analysis
have previously been implicated in breast cancer, sug-
gesting that these miRNAs have a general function in
the tumourigenic process in all breast cancers and that
they are not specific to TNBC. This is perhaps not sur-
prising, given the weak separation of the TNBC subtype
by hierarchical clustering in miRNA expression profiles
when compared to other breast tumour subtypes [28].The results of this study are highly concordant with that
of Cascione et al., with 70% (50/71) of the differentially
expressed miRNAs identified by our study also showing
differential regulation in normal versus tumour compari-
sons in their study of TNBC [27]. Differentially ex-
pressed miRNAs included members of the miR-17-92
oncogenic cluster, the let-7 family and the miR-200 fam-
ily which are known to be dysregulated in several solid
tumours, including breast cancer [29,30]. Of particular
note, the miR-17-92 cluster was recently shown to be
up-regulated in TNBC and the basal subtype [10,31]
while miR-145 and miR-199b-5p were strongly repressed
[10] consistent with our results. miR-210 and miR-21,
well known oncomiRs [7,11] were found to be over-
expressed in our study. We also observed that miRNAs
Figure 3 Validation of selected miRNAs significantly different in triple negative breast cancer with lymph node metastases. Relative
quantification of let-7b, miR-130a, miR-101, miR-26a, miR-100, miR-210, miR-26b, miR-29c and let-7a by real-time RT-PCR in normal and tumour
samples from lymph node negative and lymph node positive patients. Results are shown as a box plot of the relative normalised expression
(target/RNU44) of the target miRNA (2-ΔCt). Boxes represent the median ± interquartile range. *p < 0.05, **p < 0.01, ***p < 0.0005 and +p < 0.0001.
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18b) were over-expressed [32]; while those that have
been previously reported to be differentially expressed
between ER-positive and -negative breast cancers (in-
cluding let-7b, miR-200a, miR-21, miR-25, miR-106b)
were significantly altered in this study [32].
The immunohistochemical and molecular profiles of
TNBCs are similar to that of hereditary breast cancers
that have mutations in the BRCA1 gene [2]. In this regard,
several miRNAs identified in this study are known to par-
ticipate in the BRCA1 signalling axis including miR-146a,
miR-155 and miR-335 [33-35]. Deregulation of these miR-
NAs in TNBC may contribute to altered BRCA1 signalling
and could partly explain the similarities of these tumours
with those in which BRCA1 function is lost.miRNAs involved in LN positive TNBC
A significant and important finding from this study is
that the miRNA profiles of LN positive primary breast
cancers were strikingly distinct from that of LN negative
patients. In particular, there was an overall up-regulation
of miRNAs in LN negative patients and a dampening of
miRNA expression in LN positive patients, suggesting
that oncogenic miRNAs are associated with the develop-
ment of LN negative TNBC and in contrast, that deregu-
lated expression of tumour suppressor miRs is involved
in LN positive disease. Two enzymes, Drosha and Dicer,
are pivotal in the processing of pri-miRNA into mature
double stranded miRNA fragments [4]. Interestingly, in
breast cancer, reduced expression of Dicer has been as-
sociated with shorter metastasis-free survival and with









Wnt signaling pathway 318 16 5.69 + 0.000248
TGF-beta signaling pathway 149 10 2.66 + 0.000423
Cell cycle 22 4 0.39 + 0.00072
p53 pathway 114 7 2.04 + 0.00487
p53 pathway by glucose deprivation 25 3 0.45 + 0.0106
p53 pathway feedback loops 52 4 0.93 + 0.0148
PI3 kinase pathway 117 6 2.09 + 0.0198
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs
alpha mediated pathway
164 7 2.93 + 0.0296
EGF receptor signaling pathway 130 6 2.32 + 0.0308
De novo pyrmidine ribonucleotides biosythesis 18 2 0.32 + 0.0418
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tients [36-38]. The correlation of Dicer expression with
LN metastases in TNBC patients was not examined in
these studies [36,38]. It could be hypothesised that the
overall down-regulation of miRNAs observed in LN posi-
tive TNBCs in the current study is a result of reduced
Dicer expression, but this remains to be determined.
miRNAs as markers for metastasis
In this study, we were not seeking to identify miRNAs
that were differentially expressed in the transition of
breast cancer progression i.e. primary breast cancer to
metastasis or from ductal carcinoma in situ (DCIS) to
IDC, as previous studies have done [10,27,28,39]. In con-
trast to other studies, our analysis yielded no discrimin-
atory miRNAs when matched primary breast cancer and
LN metastases were compared suggesting that they are
remarkably similar in their miRNA profiles and support-
ing the validity of our approach. The premise of theTable 5 Correlation between miRNA expression levels and cli
Age at diagnosis Tumour
Spearman rank p-value Spearma
let-7a 0.04597 0.7932 0.07885
let-7b −0.08997 0.6073 0.08432
miR-100 −0.09418 0.5905 0.171
miR-101 0.1756 0.313 0.17
miR-126* 0.0471 0.7882 0.08945
miR-130a 0.07147 0.6833 −0.1973
miR-210 0.1029 0.5565 0.004349
miR-26a 0.05199 0.7668 0.08586
miR-26b 0.1511 0.3863 0.05724
miR-29c 0.07231 0.6797 0.1254
Values represent Spearman’s rank correlation coefficient and significant correlationscurrent study was to determine altered miRNA expres-
sion patterns in primary breast cancers that were also
present in LN metastases. We reasoned that deregulated
expression of key miRNAs that promote a highly inva-
sive phenotype would be an early event in breast cancer
progression and that these changes would be present in
both the primary and metastatic lesion. Using this ap-
proach, we identified a panel of 27 miRNAs that are
associated with metastasis to the LN. Given that the ma-
jority of these miRNAs are down-regulated, their value
as prognostic markers remains to be determined and is
the subject of ongoing investigations. However, 17/27
(63%) miRNAs are either known to be tumour suppres-
sor miRs and/or have been shown to play a role in hu-
man embryonic stem cell regulation (Additional file 1:
Table S7), supporting that deregulated expression of this
panel of miRNAs is likely to result in altered differenti-
ation states and increased invasiveness. In this regard, let-
7 family members, miR-34a and miR-205 are markedlynical variables in triple negative breast cancers
size (mm) % + ve lymph nodes











(p < 0.05) are shown in bold.
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in epithelial to mesenchymal transition [21,40,41]. In
addition, several of the miRNAs in this list have already
been shown to have prognostic value in breast cancer in-
cluding miR-210, miR-126, miR-26a, miR-125b, miR-205
and miR-214 [7-10,42-44]. Furthermore, our results are in
agreement with Cascione et al., who found that both miR-
125b and miR-497 were down-regulated and related to
survival in TNBC [27].
Within our panel of metastasis-related miRNAs are a
number of miRNAs whose functional role in breast
cancer progression has not previously been described.
These include miR-320c, miR-29c, miR-130a and miR-
195 among others. There are no reports on miR-320c
function to date and thus its possible role in promoting
LN metastasis in TNBC remains unknown. miR-29c has
previously been reported to be up-regulated in a small
cohort of breast cancer cases [11], however, we found
miR-29c to be down-regulated and associated with LN
metastasis. In agreement with our study, miR-29c is
down-regulated in chronic lymphocytic leukaemia and a
range of solid tumours including colorectal cancer where
it has been reported to decrease with cancer progression
and is a predictor of survival and early recurrence
[45,46]. miR-130a is down-regulated in a panel of ovar-
ian cancer and lung cancer cell lines that are resistant to
chemotherapies [23,24]. Moreover, it has recently been
shown to be decreased in prostate cancer and its over-
expression in prostate cancer cell lines causes the re-
pression of key oncogenic pathways such as the MAPK
pathway [47]. miR-195 was markedly down-regulated in
our study. Its re-expression in breast cancer cell lines
has recently been reported to reduce cellular prolifera-
tion and invasion, suggesting that it plays a key role in
breast cancer progression [48].
A recent study by Buffa et al., described three miRNAs
(miR-342, miR-27b, miR-150) that were prognostic for
relapse-free survival in TNBC [49]. In our hands, these
results were not replicated for LN metastasis and more-
over, these miRNAs were not differentially expressed
when breast tumour was compared to normal tissue. In
addition, miR-10b has been shown to be strongly ex-
pressed in metastatic breast cancer cells, where it regu-
lates invasion and migration [50]. However, we observed
miR-10b to be strongly down-regulated in lymph-node
positive and negative primary breast cancers and in LN
metastases, suggesting it does not contribute to breast
cancer invasiveness, and this is in strong agreement with
several recent studies [6,10,20].
We used starBASE to predict signalling pathways reg-
ulated by the 27 miRNAs associated with LN metastasis.
Interestingly, the pathways identified by this analysis
have been widely reported to be deregulated in TNBC.
In particular Wnt/β-Catenin, EGFR1 and the TGFβreceptor signalling axis are all known to be highly ex-
pressed in a large proportion of cases within the TNBC
subtype and have been proposed as alternative treatment
targets for TNBC [2,3,51]. A number of chemotherapeu-
tic agents which target these pathways are currently
under investigation in patients with TNBC, in both the
neoadjuvant and metastatic setting [52]. The findings
from our study- decreased expression of key miRNAs
which target these pathways- provides a biological mecha-
nism for up-regulation of these pathways in this breast
cancer subtype. Additionally, TP53, PIK3CA and EGFR
are among the four most commonly mutated genes asso-
ciated with aberrant expression of interacting genes in
TNBC [53], exemplifying their importance in this subtype.
The predicted regulation of these pathways by miRNAs,
as found in our study, reveals another mechanism for dis-
ruption of these pathways in TNBC.
Study design
A disadvantage of our study design is that samples were
acquired by punch biopsy, rather than isolating individ-
ual normal breast and tumour epithelial cells by laser
capture microdissection. We recognise that tissue het-
erogeneity and contamination by other non-neoplastic
cell types including adipocytes, stroma and lymphocytes
was unavoidable and that it may have contributed to the
miRNA profiles generated. Our approach of selecting
miRNAs that were only differentially expressed in pri-
mary tumours and matched LN metastases and that
were not altered in LN negative primary tumours would
have culled a large proportion of those miRNAs that are
specifically altered in inflammatory responses. Moreover,
those miRNAs that were differentially expressed simply
because of differences in cell type composition between
normal tissue (higher content of adipocytes and stroma)
when compared to tumour tissue (higher content of epi-
thelium) would have shown overlapping miRNA profiles
when both LN negative and LN positive primary tu-
mours were compared to matched normal tissues (10
miRNAs, Figure 2C) and were not included in our list of
miRNAs related to metastasis (Table 3). Therefore, be-
cause of this careful process of elimination, we consider
the miRNAs identified in this study (Table 3) are
strongly representative of the invasive capacity of the
primary tumour.
Given that the sample size used in this study is rela-
tively small, conclusions cannot be drawn about the rela-
tionship of these miRNAs to prognosis or their
specificity to the TNBC subtype. However, the tumours
are homogenous with regards to size, hormone receptor
status and histological grade. Furthermore, the size of
this cohort (n = 35) is in line with several recent studies
investigating the prognostic value of miRNAs in TNBC
(Buffa et al., n = 37; Farazi et al., n = 48; Radojocic et al.,
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http://www.biomedcentral.com/1471-2407/14/51n = 49) [20,28,49] and represents the only study to date
that has analysed the full repertoire of miRNAs in lymph
node positive and negative TNBC samples separately
compared to matched normal adjacent tissue. The
uniqueness of our study design was highly advantageous
for delineating critical differences in miRNA profiles be-
tween LN positive and negative primary tumours, which
would have been missed if: 1) matched normal adjacent
tissue was not used and 2) only primary tumours from
LN positive versus LN negative patients were compared
to one another. In a recent study, Farazi and colleagues
showed that there was no difference in miRNA profiles
of primary breast tumours between TNBC patients who
relapsed when compared to those who did not [28]. In-
deed, we also found that no miRNAs were differentially
expressed when LN negative versus positive primary tu-
mours were directly compared using our statistical cut-
offs. Further to this, in our study no miRNAs were
found to be differentially expressed when normal tissue
from LN positive patients was compared to that of LN
negative patients. As such, the distinct miRNA profiles
generated when LN negative and LN positive primary
tumours were each separately compared to matched
normal adjacent tissues are likely to reflect small, but
critical changes in the regulation of miRNAs that are es-
sential for the development of each of these respective
phenotypes. Given that any LN involvement (regardless
of number) is associated with worse disease-free and
overall survival in TNBC [14], identification of molecu-
lar determinants such as miRNAs, that contribute to this
highly invasive phenotype is urgently needed.Conclusions
This study has provided novel insight into the repertoire
of miRNAs that contribute to the initiation of and pro-
gression to LN metastasis in TNBC. These miRNAs may
serve as markers for metastasis or treatment targets in
the future.Additional file
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